Form 4: Silo Pharma CEO Boosts Stake with Share Purchases
Insider Transaction Report
Silo Pharma's CEO, Eric Weisblum, increased his direct ownership in the company by purchasing 12,000 shares of common stock over two days in November 2025.
Summary
- Eric Weisblum, the Chief Executive Officer and a Director of Silo Pharma, Inc. (SILO), acquired additional shares of the company's common stock.
- On November 18, 2025, Mr. Weisblum purchased 7,500 shares of common stock at a weighted average price of $0.4033 per share.
- On November 19, 2025, he purchased an additional 4,500 shares of common stock at a weighted average price of $0.405 per share.
- These transactions increased his direct beneficial ownership to 209,932 shares of common stock following the reported purchases.
- The purchases were made in multiple transactions within price ranges of $0.4000 to $0.4050 on November 18, 2025, and $0.3975 to $0.4100 on November 19, 2025.
Sentiment
Score: 8
Explanation: The sentiment is highly positive due to significant insider buying by the CEO, which typically signals strong confidence in the company's future prospects and potential undervaluation.
Positives
- The CEO's direct purchase of company stock signals strong confidence in Silo Pharma's future prospects and potential undervaluation.
- Increased insider ownership aligns management's interests more closely with those of shareholders.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance, but the insider purchases implicitly suggest a positive outlook from management regarding the company's future performance.
Industry Context
Insider buying, particularly by a CEO, is often interpreted by the market as a strong vote of confidence in the company's strategic direction and future value. This action by Silo Pharma's CEO aligns with a general market observation that insiders tend to buy when they believe the stock is undervalued or when significant positive developments are anticipated, a trend seen across various industries.
Stakeholder Impact
- Shareholders: May view the CEO's increased stake as a positive indicator of future stock performance and management commitment, potentially boosting investor confidence.
- Employees: Could interpret the CEO's investment as a sign of stability and belief in the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 11/18/2025 | Eric Weisblum purchased 7,500 shares of Silo Pharma Common Stock at a weighted average price of $0.4033. |
| 11/19/2025 | Eric Weisblum purchased 4,500 shares of Silo Pharma Common Stock at a weighted average price of $0.405. |
| 11/20/2025 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed and filed. |
Recommendation
buyThe CEO's decision to significantly increase his personal stake in Silo Pharma through open market purchases suggests a strong belief in the company's intrinsic value and future growth potential. This insider buying often precedes positive developments or indicates that the stock is currently undervalued, making it an attractive 'buy' signal for seasoned investors.
Keywords
Silo Pharma, SILO, Eric Weisblum, Insider Buying, Stock Purchase, CEO, Director, Common Stock, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.